Cancer serum index: a useful nonspecific test as a parameter in multimodality screening and assessment of patients with cancer of the prostate.
A satisfactory, simple test for screening and monitoring of patients with prostatic cancer is still being sought. We suggest the use of a nonspecific test in combination with other tests. The ratio of two serum proteins (alpha 1 acid glycoprotein [AGP] and prealbumin [PAB]), may be useful markers for a cancer serum index (CSI). By separating serum components by gradient polyacrylamide gel electrophoresis, staining and quantitating these proteins by scanning densitometry, and dividing the area of AGP by that of PAB, indices can be obtained. In a test of sera from 450 patients with prostatic cancer, other urologic problems, and normal controls, CSIs of 360 sera presently decoded were found to be: (Formula: see text). The CSI should prove highly valuable when used in combination with selected prostatic cancer tests.
D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood; D008297:Male; D009367:Neoplasm Staging; D009961:Orosomucoid / Q000097:blood*; D011228:Prealbumin / Q000378:metabolism*; D011470:Prostatic Hyperplasia / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood*; D012709:Serum Albumin / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000097:blood; D014570:Urologic Diseases / Q000097:blood
D009961:Orosomucoid; D011228:Prealbumin; D012709:Serum Albumin